Caris Life Sciences (CAI) Change in Accured Expenses (2024 - 2026)

Caris Life Sciences' Change in Accured Expenses history runs 3 years deep, the most recent figure standing at -$15.0 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 680.5% year-over-year to -$15.0 million in Q1 2026; TTM through Mar 2026 was -$6.1 million, a N/A change from a year earlier, with the FY2025 full-year figure at $11.5 million, up 1329.51% from the prior year.
• Change in Accured Expenses fell to -$15.0 million in Q1 2026 per CAI's latest filing, from $29.3 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $29.3 million in Q4 2025 and bottomed at -$21.3 million in Q2 2025.
• The 3-year median for Change in Accured Expenses is $889000.0 (2025), against an average of -$732000.0.
• Across the five-year window, Change in Accured Expenses jumped 105.4% in 2025 and sank 680.5% in 2026, its largest moves.
• Year by year, Change in Accured Expenses stood at $14.8 million in 2024, then surged by 97.46% to $29.3 million in 2025, then slumped by 151.17% to -$15.0 million in 2026.
• Per Business Quant, the three latest CAI Change in Accured Expenses figures stand at -$15.0 million (Q1 2026), $29.3 million (Q4 2025), and $889000.0 (Q3 2025).